Serum neurofilament light as a biomarker in progressive multiple sclerosis
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
There is an unmet need in multiple sclerosis (MS) therapy for treatments to stop progressive disability. The development of treatments may be accelerated if novel biomarkers are developed to overcome the limitations of traditional imaging outcomes revealed in early phase trials. In January 2019, the International Progressive MS Alliance convened a standing expert panel to consider potential tissue fluid biomarkers in MS in general and in progressive MS specifically. The panel focused their attention on neurofilament light chain (NfL) in serum or plasma, examining data from both relapsing and progressive MS. Here, we report the initial conclusions of the panel and its recommendations for further research. Serum NfL (sNfL) is a plausible marker of neurodegeneration that can be measured accurately, sensitively, and reproducibly, but standard procedures for sample processing and analysis should be established. Findings from relapsing and progressive cohorts concur and indicate that sNfL concentrations correlate with imaging and disability measures, predict the future course of the disease, and can predict response to treatment. Importantly, disease activity from active inflammation (i.e., new T2 and gadolinium-enhancing lesions) is a large contributor to sNfL, so teasing apart disease activity from the disease progression that drives insidious disability progression in progressive MS will be challenging. More data are required on the effects of age and comorbidities, as well as the relative contributions of inflammatory activity and other disease processes. The International Progressive MS Alliance is well positioned to advance these initiatives by connecting and supporting relevant stakeholders in progressive MS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neurofilaments as biomarkers in neurological disorders
Khalil, M., Teunissen, C. E., Otto, M., Piehl, F., Sormani, M. P., Gattringer, T., Barro, C., Kappos, L., Comabella, M., Fazekas, F., et al. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0058-z · Cited by 1,988 · cited 3×
“Their concentrations are elevated across a wide range of neurologic diseases, consistent with release on axonal damage frommultiple causes.(13) Although the most widely used monoclonal antibodies for NfL(14) have been highly specific in NfL knock-out animal experiments,(15) the extent to which intact NfL and its degra…”
BackgroundResultInfluentialSelf-citationSerum neurofilament light: a biomarker of neuronal damage in multiple sclerosis
Disanto, G., Barro, C., Benkert, P., Naegelin, Y., Schädelin, S., Giardiello, A., Zecca, C., Blennow, K., Zetterberg, H., Leppert, D., et al. (2017) · Annals of Neurology · doi:10.1002/ana.24954 · Cited by 1,164 · cited 4×
“2% per year between ages 18 and 70 years in healthy controls.(19,23,26) The reasons for this age-dependent increase are not well understood.”
BackgroundMethodInfluentialSelf-citationAssociation of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease
Mattsson, N., Andreasson, U., Zetterberg, H., Blennow, K., & Initiative, F. T. A. D. N. (2017) · JAMA Neurology · doi:10.1001/jamaneurol.2016.6117 · Cited by 1,070
Dominantly Inherited Alzheimer Network, Preische, O., Schultz, S. A., Apel, A., Kuhle, J., Kaeser, S. A., Barro, C., Gräber, S., Kuder-Buletta, E., LaFougere, C., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0304-3 · Cited by 927 · cited 1×
“In patients with Alzheimer disease and amyotrophic lateral sclerosis, increasing mean serum concentrations occur months or years before the emergence of the first clinical manifestations.(35,36) Similarly, an increased CSF NfL concentration in radiologically isolated syndrome is a risk factor for later transition to c…”
BackgroundSelf-citationBridel, C., van Wieringen, W. N., Zetterberg, H., Tijms, B. M., Teunissen, C. E., and the NFL Group, Alvarez-Cermeño, J. C., Andreasson, U., Axelsson, M., Bäckström, D. C., et al. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2019.1534 · Cited by 764 · cited 13×
“2% per year between ages 18 and 70 years in healthy controls.(19,23,26) The reasons for this age-dependent increase are not well understood.”
BackgroundInfluentialSelf-citationKuhle, J., Barro, C., Andreasson, U., Derfuss, T., Lindberg, R., Sandelius, Å., Liman, V., Norgren, N., Blennow, K., & Zetterberg, H. (2016) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2015-1195 · Cited by 740
Barro, C., Benkert, P., Disanto, G., Tsagkas, C., Amann, M., Naegelin, Y., Leppert, D., Gobbi, C., Granziera, C., Yaldizli, Ö., et al. (2018) · Brain · doi:10.1093/brain/awy154 · Cited by 517
Self-citationGisslén, M., Price, R. W., Andreasson, U., Norgren, N., Nilsson, S., Hagberg, L., Fuchs, D., Spudich, S., Blennow, K., & Zetterberg, H. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2015.11.036 · Cited by 481
Bacioglu, M., Maia, L. F., Preische, O., Schelle, J., Apel, A., Kaeser, S. A., Schweighauser, M., Eninger, T., Lambert, M., Pilotto, A., et al. (2016) · Neuron · doi:10.1016/j.neuron.2016.05.018 · Cited by 435
Monitoring disease activity in multiple sclerosis using serum neurofilament light protein
Novakova, L., Zetterberg, H., Sundström, P., Axelsson, M., Khademi, M., Gunnarsson, M., Malmeström, C., Svenningsson, A., Olsson, T., Piehl, F., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000004683 · Cited by 426
Cited by
The potential of serum neurofilament as biomarker for multiple sclerosis
Bittner, S., Oh, J., Havrdová, E. K., Tintoré, M., & Zipp, F. (2021) · Brain · doi:10.1093/brain/awab241 · Cited by 229
Barro, C., Healy, B. C., Liu, Y., Saxena, S., Paul, A., Polgar-Turcsanyi, M., Guttmann, C. R. G., Bakshi, R., Kropshofer, H., Weiner, H. L., et al. (2023) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000200052 · Cited by 176
Blood Neurofilament Light Chain: The Neurologist’s Troponin?
Thebault, S., Booth, R. A., & Freedman, M. S. (2020) · Biomedicines · doi:10.3390/biomedicines8110523 · Cited by 101
“Given the lack of useful biomarkers otherwise for progressive types of MS, NfL is increasingly seen as an important secondary endpoint in phase 2 and 3 studies of treatments [81].”
Backgroundvan den Bosch, A., Fransen, N., Mason, M., Rozemuller, A. J., Teunissen, C., Smolders, J., & Huitinga, I. (2022) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000001154 · Cited by 58
“13 21 NfL levels correlate with clinical relapses and radiological biomarkers of inflammatory disease activity, as it reflects the amount of gadolinium-enhancing lesions, 18,20 the amount of paramagnetic rim MRI lesions in the absence of gadolinium-enhancing lesions, 22 as well as disease…”
Self-citationBenatar, M., Ostrow, L. W., Lewcock, J. W., Bennett, F., Shefner, J., Bowser, R., Larkin, P., Bruijn, L., & Wuu, J. (2024) · Annals of Neurology · doi:10.1002/ana.26860 · Cited by 52
Metadata
- Authors
- Kapoor, R., Smith, K. E., Allegretta, M., Arnold, D. L., Carroll, W., Comabella, M., Furlan, R., Harp, C., Kuhle, J., Leppert, D., Plavina, T., Sellebjerg, F., Sincock, C., Teunissen, C. E., Topalli, I., von Raison, F., Walker, E., & Fox, R. J.
- Venue
- Neurology
- Published
- 2020-09-08
- Volume
- 95
- Issue
- 10
- Pages
- 436-444
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W3042931334
- Cited by
- 156
- References
- 13
- FWCI
- 14.14
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Serum neurofilament light as a biomarker in progressive multiple sclerosis. https://app.cochat.ai/papers/10.1212/wnl.0000000000010346
- The paper
- Kapoor, R., Smith, K. E., Allegretta, M., Arnold, D. L., Carroll, W., Comabella, M., Furlan, R., Harp, C., Kuhle, J., Leppert, D., Plavina, T., Sellebjerg, F., Sincock, C., Teunissen, C. E., Topalli, I., von Raison, F., Walker, E., & Fox, R. J. (2020). Serum neurofilament light as a biomarker in progressive multiple sclerosis. Neurology. https://doi.org/10.1212/wnl.0000000000010346
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.